Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids
Jump to navigation
Jump to search
Template documentation
Route | Medication | Major brand names | Dosage range | |
---|---|---|---|---|
Oral | Template:No selflink | Danocrine | 100–800 mg/day | |
Template:No selflink | Maxibolin, Orabolin | 2–8 mg/day | ||
Template:No selflink | Halotestin, Ora-Testryl, Ultandren | 2–40 mg/day | ||
Template:No selflink | Proviron | 25–150 mg/day | ||
Template:No selflink | Dianabol | 2.5–15 mg/day | ||
Template:No selflink | Primobolan | 10–150 mg/day | ||
Template:No selflink | Android, Metandren, Testred | 1.5–200 mg/day | ||
Template:No selflink | Nilevar, Pronabol | 20–30 mg/day | ||
Template:No selflink | Anavar, Oxandrin | 2.5–20 mg/day | ||
Template:No selflink | Anadrol, Anapolon | 1–5 mg/kg/day (50–150 mg/day) | ||
Template:No selflink | Winstrol | 2–6 mg/day | ||
Template:No selflinka | – | 400–800 mg/day (in divided doses) | ||
Template:No selflink | Andriol, Jatenzo | 40–80 mg/2–4x day (with food) | ||
Injection | Template:No selflink | Drolban, Masteril, Masteron | 100 mg 3x/week | |
Template:No selflink | Primobolan Depot | 25–100 mg/week | ||
Template:No selflink | Deca-Durabolin | 12.5–200 mg/week (total) | ||
Template:No selflink | Durabolin | 6.25–200 mg/week (total) | ||
Template:No selflink | Winstrol Depot | 50 mg 1x/2–3 weeks | ||
Template:No selflink | Andronaq, Sterotate, Virosterone | 25–100 mg 2–3x/week | ||
Template:No selflink | Depo-Testosterone | 50–400 mg 1x/1–4 weeks | ||
Template:No selflink | Delatestryl | 50–400 mg 1x/1–4 weeks | ||
Template:No selflink | Testoviron | 25–50 mg 2–3x/week | ||
Template:No selflink | Aveed, Nebido | 750–1,000 mg 1x/10–14 weeks | ||
Template:No selflink | Hexabolan, Parabolan | 75 mg/1.5 weeks | ||
Note: Dosage ranges are for varying indications and are not necessarily equivalent. Footnotes: a = Studied for male hypogonadism but never marketed. For comparison purposes. Sources: General: [1][2][3][4][5][6][7][8] Additional: [9][10] |

See also
- Template:Androgen replacement therapy formulations and dosages used in men
- Template:Medications and dosages used in hormone therapy for transgender men
- Template:Androgen replacement therapy formulations and dosages used in women
- Template:Androgen/anabolic steroid dosages for breast cancer
References
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 1 December 2019.
- ↑ Richard Joseph Hamilton; Nancy Anastasi Duffy; Daniel Stone (2014). Tarascon Pharmacopoeia. Jones & Bartlett Publishers. pp. 174–. ISBN 978-1-284-05671-6.
- ↑ Susan M. Ford; Sally S. Roach (2010). Roach's Introductory Clinical Pharmacology. Lippincott Williams & Wilkins. pp. 499–. ISBN 978-1-60547-633-9.
- ↑ Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1358–. ISBN 978-1-60913-345-0.
- ↑ Brent C Mangus; Michael G Miller (11 January 2005). Pharmacology Application in Athletic Training. F.A. Davis. pp. 151–. ISBN 978-0-8036-2027-8.
- ↑ John A. Thomas (6 December 2012). Drugs, Athletes, and Physical Performance. Springer Science & Business Media. pp. 20–. ISBN 978-1-4684-5499-4.
- ↑ William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. ISBN 978-0-9828280-1-4.
- ↑ Burkett, Lee N.; Falduto, Michael T. (1984). "Steroid Use by Athletes in a Metropolitan Area". The Physician and Sportsmedicine. 12 (8): 69–74. doi:10.1080/00913847.1984.11701923. ISSN 0091-3847.
- ↑ J. Bain; Wolf-Bernhard Schill; L. Schwarzstein (6 December 2012). Treatment of Male Infertility. Springer Science & Business Media. pp. 176–177. ISBN 978-3-642-68223-0.
- ↑ Snyder, P J (1984). "Clinical Use of Androgens". Annual Review of Medicine. 35 (1): 207–217. doi:10.1146/annurev.me.35.020184.001231. ISSN 0066-4219.
Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |